The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Personalized Medicine and Epigenomics-Global Market Insights and Sales Trends 2025
Synopsis
The global Personalized Medicine and Epigenomics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Personalized Medicine and Epigenomics in various end use industries. The expanding demands from the Oncology, Non-Oncology and Cancer Drug Technology,, are propelling Personalized Medicine and Epigenomics market. Reagents, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Kits segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Personalized Medicine and Epigenomics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Personalized Medicine and Epigenomics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Personalized Medicine and Epigenomics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Personalized Medicine and Epigenomics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Personalized Medicine and Epigenomics covered in this report include Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, BAYER AG, Bio Vision, Celgene Corp., Emd Millipore and Epigenomics AG, etc.
The global Personalized Medicine and Epigenomics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Global Personalized Medicine and Epigenomics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Personalized Medicine and Epigenomics market, Segment by Type:
Reagents
Kits
Instruments
Enzymes
Services
Global Personalized Medicine and Epigenomics market, by Application
Oncology
Non-Oncology
Cancer Drug Technology
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Personalized Medicine and Epigenomics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Personalized Medicine and Epigenomics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Personalized Medicine and Epigenomics in various end use industries. The expanding demands from the Oncology, Non-Oncology and Cancer Drug Technology,, are propelling Personalized Medicine and Epigenomics market. Reagents, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Kits segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Personalized Medicine and Epigenomics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Personalized Medicine and Epigenomics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Personalized Medicine and Epigenomics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Personalized Medicine and Epigenomics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Personalized Medicine and Epigenomics covered in this report include Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, BAYER AG, Bio Vision, Celgene Corp., Emd Millipore and Epigenomics AG, etc.
The global Personalized Medicine and Epigenomics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Global Personalized Medicine and Epigenomics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Personalized Medicine and Epigenomics market, Segment by Type:
Reagents
Kits
Instruments
Enzymes
Services
Global Personalized Medicine and Epigenomics market, by Application
Oncology
Non-Oncology
Cancer Drug Technology
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Personalized Medicine and Epigenomics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Personalized Medicine and Epigenomics
1.1 Personalized Medicine and Epigenomics Market Overview
1.1.1 Personalized Medicine and Epigenomics Product Scope
1.1.2 Personalized Medicine and Epigenomics Market Status and Outlook
1.2 Global Personalized Medicine and Epigenomics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Personalized Medicine and Epigenomics Market Size by Region (2018-2029)
1.4 Global Personalized Medicine and Epigenomics Historic Market Size by Region (2018-2023)
1.5 Global Personalized Medicine and Epigenomics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Personalized Medicine and Epigenomics Market Size (2018-2029)
1.6.1 North America Personalized Medicine and Epigenomics Market Size (2018-2029)
1.6.2 Europe Personalized Medicine and Epigenomics Market Size (2018-2029)
1.6.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2018-2029)
1.6.4 Latin America Personalized Medicine and Epigenomics Market Size (2018-2029)
1.6.5 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2018-2029)
2 Personalized Medicine and Epigenomics Market by Type
2.1 Introduction
2.1.1 Reagents
2.1.2 Kits
2.1.3 Instruments
2.1.4 Enzymes
2.1.5 Services
2.2 Global Personalized Medicine and Epigenomics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2018-2023)
2.2.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Personalized Medicine and Epigenomics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Personalized Medicine and Epigenomics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Personalized Medicine and Epigenomics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Personalized Medicine and Epigenomics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Personalized Medicine and Epigenomics Revenue Breakdown by Type (2018-2029)
3 Personalized Medicine and Epigenomics Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Non-Oncology
3.1.3 Cancer Drug Technology
3.2 Global Personalized Medicine and Epigenomics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2018-2023)
3.2.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Personalized Medicine and Epigenomics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Personalized Medicine and Epigenomics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Personalized Medicine and Epigenomics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Personalized Medicine and Epigenomics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Personalized Medicine and Epigenomics Revenue Breakdown by Application (2018-2029)
4 Personalized Medicine and Epigenomics Competition Analysis by Players
4.1 Global Personalized Medicine and Epigenomics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2022)
4.3 Date of Key Players Enter into Personalized Medicine and Epigenomics Market
4.4 Global Top Players Personalized Medicine and Epigenomics Headquarters and Area Served
4.5 Key Players Personalized Medicine and Epigenomics Product Solution and Service
4.6 Competitive Status
4.6.1 Personalized Medicine and Epigenomics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott Laboratories
5.1.1 Abbott Laboratories Profile
5.1.2 Abbott Laboratories Main Business
5.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Products, Services and Solutions
5.1.4 Abbott Laboratories Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Laboratories Recent Developments
5.2 Affymetrix
5.2.1 Affymetrix Profile
5.2.2 Affymetrix Main Business
5.2.3 Affymetrix Personalized Medicine and Epigenomics Products, Services and Solutions
5.2.4 Affymetrix Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.2.5 Affymetrix Recent Developments
5.3 Agilent Technologies
5.3.1 Agilent Technologies Profile
5.3.2 Agilent Technologies Main Business
5.3.3 Agilent Technologies Personalized Medicine and Epigenomics Products, Services and Solutions
5.3.4 Agilent Technologies Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.3.5 Astellas Pharmaceuticals Recent Developments
5.4 Astellas Pharmaceuticals
5.4.1 Astellas Pharmaceuticals Profile
5.4.2 Astellas Pharmaceuticals Main Business
5.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Products, Services and Solutions
5.4.4 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.4.5 Astellas Pharmaceuticals Recent Developments
5.5 BAYER AG
5.5.1 BAYER AG Profile
5.5.2 BAYER AG Main Business
5.5.3 BAYER AG Personalized Medicine and Epigenomics Products, Services and Solutions
5.5.4 BAYER AG Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.5.5 BAYER AG Recent Developments
5.6 Bio Vision
5.6.1 Bio Vision Profile
5.6.2 Bio Vision Main Business
5.6.3 Bio Vision Personalized Medicine and Epigenomics Products, Services and Solutions
5.6.4 Bio Vision Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.6.5 Bio Vision Recent Developments
5.7 Celgene Corp.
5.7.1 Celgene Corp. Profile
5.7.2 Celgene Corp. Main Business
5.7.3 Celgene Corp. Personalized Medicine and Epigenomics Products, Services and Solutions
5.7.4 Celgene Corp. Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.7.5 Celgene Corp. Recent Developments
5.8 Emd Millipore
5.8.1 Emd Millipore Profile
5.8.2 Emd Millipore Main Business
5.8.3 Emd Millipore Personalized Medicine and Epigenomics Products, Services and Solutions
5.8.4 Emd Millipore Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.8.5 Emd Millipore Recent Developments
5.9 Epigenomics AG
5.9.1 Epigenomics AG Profile
5.9.2 Epigenomics AG Main Business
5.9.3 Epigenomics AG Personalized Medicine and Epigenomics Products, Services and Solutions
5.9.4 Epigenomics AG Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.9.5 Epigenomics AG Recent Developments
5.10 Epigentex
5.10.1 Epigentex Profile
5.10.2 Epigentex Main Business
5.10.3 Epigentex Personalized Medicine and Epigenomics Products, Services and Solutions
5.10.4 Epigentex Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.10.5 Epigentex Recent Developments
5.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
5.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Profile
5.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Main Business
5.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Products, Services and Solutions
5.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Developments
5.12 Gilead Sciences
5.12.1 Gilead Sciences Profile
5.12.2 Gilead Sciences Main Business
5.12.3 Gilead Sciences Personalized Medicine and Epigenomics Products, Services and Solutions
5.12.4 Gilead Sciences Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.12.5 Gilead Sciences Recent Developments
5.13 Glaxosmithkline
5.13.1 Glaxosmithkline Profile
5.13.2 Glaxosmithkline Main Business
5.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Products, Services and Solutions
5.13.4 Glaxosmithkline Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.13.5 Glaxosmithkline Recent Developments
5.14 Illumina Inc.
5.14.1 Illumina Inc. Profile
5.14.2 Illumina Inc. Main Business
5.14.3 Illumina Inc. Personalized Medicine and Epigenomics Products, Services and Solutions
5.14.4 Illumina Inc. Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.14.5 Illumina Inc. Recent Developments
5.15 Johnson & Johnson
5.15.1 Johnson & Johnson Profile
5.15.2 Johnson & Johnson Main Business
5.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Products, Services and Solutions
5.15.4 Johnson & Johnson Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.15.5 Johnson & Johnson Recent Developments
5.16 Karus Therapeutics Limited
5.16.1 Karus Therapeutics Limited Profile
5.16.2 Karus Therapeutics Limited Main Business
5.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Products, Services and Solutions
5.16.4 Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.16.5 Karus Therapeutics Limited Recent Developments
5.17 Laboratory Corp. Of America Holdings
5.17.1 Laboratory Corp. Of America Holdings Profile
5.17.2 Laboratory Corp. Of America Holdings Main Business
5.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Products, Services and Solutions
5.17.4 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.17.5 Laboratory Corp. Of America Holdings Recent Developments
5.18 LES Laboratoires Servier
5.18.1 LES Laboratoires Servier Profile
5.18.2 LES Laboratoires Servier Main Business
5.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Products, Services and Solutions
5.18.4 LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.18.5 LES Laboratoires Servier Recent Developments
5.19 Merck
5.19.1 Merck Profile
5.19.2 Merck Main Business
5.19.3 Merck Personalized Medicine and Epigenomics Products, Services and Solutions
5.19.4 Merck Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.19.5 Merck Recent Developments
5.20 Naturewise Biotech & Medicals Corp.
5.20.1 Naturewise Biotech & Medicals Corp. Profile
5.20.2 Naturewise Biotech & Medicals Corp. Main Business
5.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Products, Services and Solutions
5.20.4 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.20.5 Naturewise Biotech & Medicals Corp. Recent Developments
5.21 Novartis Pharma AG
5.21.1 Novartis Pharma AG Profile
5.21.2 Novartis Pharma AG Main Business
5.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Products, Services and Solutions
5.21.4 Novartis Pharma AG Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.21.5 Novartis Pharma AG Recent Developments
5.22 Oncolys Biopharma Inc.
5.22.1 Oncolys Biopharma Inc. Profile
5.22.2 Oncolys Biopharma Inc. Main Business
5.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Products, Services and Solutions
5.22.4 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.22.5 Oncolys Biopharma Inc. Recent Developments
5.23 Orchid Chemicals & Pharmaceuticals Limited
5.23.1 Orchid Chemicals & Pharmaceuticals Limited Profile
5.23.2 Orchid Chemicals & Pharmaceuticals Limited Main Business
5.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Products, Services and Solutions
5.23.4 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Developments
5.24 Progen Pharmaceuticals Limited
5.24.1 Progen Pharmaceuticals Limited Profile
5.24.2 Progen Pharmaceuticals Limited Main Business
5.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Products, Services and Solutions
5.24.4 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.24.5 Progen Pharmaceuticals Limited Recent Developments
5.25 Quest Diagnostics
5.25.1 Quest Diagnostics Profile
5.25.2 Quest Diagnostics Main Business
5.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Products, Services and Solutions
5.25.4 Quest Diagnostics Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.25.5 Quest Diagnostics Recent Developments
5.26 Roche Holding AG
5.26.1 Roche Holding AG Profile
5.26.2 Roche Holding AG Main Business
5.26.3 Roche Holding AG Personalized Medicine and Epigenomics Products, Services and Solutions
5.26.4 Roche Holding AG Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.26.5 Roche Holding AG Recent Developments
5.27 Rubicon Genomics
5.27.1 Rubicon Genomics Profile
5.27.2 Rubicon Genomics Main Business
5.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Products, Services and Solutions
5.27.4 Rubicon Genomics Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.27.5 Rubicon Genomics Recent Developments
5.28 Takeda Pharmaceutical Company Limited
5.28.1 Takeda Pharmaceutical Company Limited Profile
5.28.2 Takeda Pharmaceutical Company Limited Main Business
5.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Products, Services and Solutions
5.28.4 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue (US$ Million) & (2018-2023)
5.28.5 Takeda Pharmaceutical Company Limited Recent Developments
6 North America
6.1 North America Personalized Medicine and Epigenomics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Personalized Medicine and Epigenomics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Personalized Medicine and Epigenomics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Personalized Medicine and Epigenomics Market Dynamics
11.1 Personalized Medicine and Epigenomics Industry Trends
11.2 Personalized Medicine and Epigenomics Market Drivers
11.3 Personalized Medicine and Epigenomics Market Challenges
11.4 Personalized Medicine and Epigenomics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Industrial Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
